- Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos’ point-of-care CAR-T product candidate in the
San Francisco area - Agreement follows previously announced collaboration with Landmark Bio for decentralized CAR-T manufacturing in the
Boston area
Under the terms of the agreement, Thermo Fisher will provide GMP manufacturing as well as BioServices and Specialty Logistics for Galapagos’ CAR-T hemato-oncology clinical program in the
“As we continue to execute on our global CAR-T expansion strategy, we are very pleased to collaborate with Thermo Fisher, a leader in accelerating life sciences research and the development of life-changing therapies,” said Dr.
“This collaboration marks the start of an exciting journey to support Galapagos with their decentralized manufacturing strategy,” stated
Financial terms of the agreement are not disclosed.
About Galapagos’ decentralized CAR-T manufacturing platform
Galapagos’ decentralized, innovative point-of-care CAR-T manufacturing platform offers the potential for the administration of fit cells within a median vein-to-vein time of 7 days, greater physician control and exceptional patient experience. The platform consists of an end-to-end xCellit™ workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control testing and release strategy.
About Galapagos
We are a global biotechnology company with operations in
Contact
Media inquiries: Marieke Vermeersch +32 479 490 603 media@glpg.com | Investor inquiries: +1 781 296 1143 ir@glpg.com Sandra Cauwenberghs ir@glpg.com |
Forward-looking statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements are often, but not always, made through the use of words or phrases such as “will,” “aim,” “goal,” and any similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding Galapagos’ collaboration with Thermo Fisher. Forward-looking statements may involve unknown and known risks, uncertainties and other factors which might cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks, uncertainties and other factors include, without limitation, the risk that Galapagos’ expectations regarding the collaboration with Thermo Fisher, including the potential benefits of such [collaboration], may be incorrect, the inherent uncertainties associated with competitive developments, and regulatory approval requirements, risks associated with Galapagos' reliance on collaborations with third parties (including its collaboration partner Lonza), as well as those risks and uncertainties identified in Galapagos’ Annual Report on Form 20-F for the year ended
1 Throughout this press release, ‘Dr. Paul Stoffels’ should be read as ‘Dr.
Attachment
- Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the
U.S.
© OMX, source